Emergent BioSolutions | EBS - Ebitda


Emergent BioSolutions reported $-113.5M in EBITDA for its fiscal quarter ending in March of 2023.





Ebitda Change Date
Acadia Pharmaceuticals USD -1.62M 21.94M Mar/2026
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
ALKERMES USD 139.22M 58.96M Jun/2026
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
Amarin USD 12.54M 28.57M Jun/2025
ANI Pharmaceuticals USD 71.6M 6.69M Jun/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Exelixis USD 255.4M 2.89M Jun/2026
Glaxosmithkline GBP 2.77B 1.98B Mar/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
Lexicon Pharmaceuticals USD -12.04M 15.95M Sep/2025
Lonza CHF 1.01B 54M Dec/2025
Merck USD -1.54B 7.84B Mar/2026
Moderna USD -1.26B 468M Mar/2026
Myriad Genetics USD 14.3M 4M Dec/2025
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Pacira USD 48.67M 8.43M Jun/2026
Pfizer USD 6.01B 18M Jun/2026
PTC Therapeutics USD 61.98M 132.97M Mar/2026
Sanofi EUR 3.69B 375M Jun/2026
Sarepta Therapeutics USD 375.48M 627.68M Mar/2026
United Therapeutics USD 355M 11.1M Jun/2026
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024